Case Studies: Several Patent And Registration Litigations Highlight What Not To Do In China
This article was originally published in PharmAsia News
Executive SummaryBEIJING - It is a common refrain now for companies that do business in China that the country's intellectual property protection regime, while not perfect, is improving. But a recent conference on regulatory and legal issues in Beijing provided some discouraging examples about the challenges companies face in dealing with patent litigation and import certification in China
You may also be interested in...
Translating The Foreign Corrupt Practices Act Into Practice: U.S. DoJ/SEC Offer Pragmatic Enforcement Guide
The FCPA resource guide gives examples of cases the DoJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program; PhRMA, GPhA among groups that were asking for more clarity.